Oruka Therapeutics (ORKA) Interest Expenses (2010 - 2022)
Oruka Therapeutics (ORKA) posted quarterly Interest Expenses of $161.0 million for Q1 2026, up 3322.34% year-over-year from $4.7 million in Q1 2025, and up 374288.37% quarter-over-quarter from $43000.0 in Q4 2025.
Powered by 
Analysis
Oruka Therapeutics (ORKA) Interest Expenses (2010 - 2022) Analysis & Trends
Oruka Therapeutics' Interest Expenses history runs 17 years deep, the most recent figure standing at $161.0 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 3322.34% year-over-year to $161.0 million; the TTM figure through Mar 2026 stood at $161.0 million (up 3322.34% YoY), while the FY2025 annual figure was $70.0 million, up 228.22% from the prior year.
- Interest Expenses for Q1 2026 stood at $161.0 million, up from $43000.0 in the prior quarter.
- The five-year high for Interest Expenses was $161.0 million in Q1 2026, with the low at -$32.3 million in Q4 2024.
- The 5-year median for Interest Expenses is $423500.0 (2022), against an average of $13.4 million.
- Peak annual rise in Interest Expenses reached 34122.22% in 2024, while the deepest fall reached 124330.77% in 2024.
- Oruka Therapeutics' Interest Expenses stood at $65000.0 in 2022, then slumped by 60.0% to $26000.0 in 2023, then sank by 124330.77% to -$32.3 million in 2024, then jumped by 100.13% to $43000.0 in 2025, then soared by 374288.37% to $161.0 million in 2026.
- Business Quant data shows ORKA's Interest Expenses at $161.0 million in Q1 2026, $43000.0 in Q4 2025, and $30.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Oruka Therapeutics | 5.87 Bn | 4.14 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | 3,000.00 |
| Mar 31, 2022 | 2,000.00 |
| Sep 30, 2020 | 2,000.00 |
| Jun 30, 2020 | 3,000.00 |
| Mar 31, 2020 | 4,000.00 |
| Sep 30, 2019 | 1,000.00 |
| Jun 30, 2019 | 3,000.00 |
| Mar 31, 2019 | 3,000.00 |
| Sep 30, 2018 | 2,000.00 |
| Jun 30, 2018 | 3,000.00 |
| Mar 31, 2018 | 3,000.00 |
| Sep 30, 2017 | 2,000.00 |
| Jun 30, 2017 | 2,000.00 |
| Mar 31, 2017 | 2,000.00 |
| Sep 30, 2015 | 1,000.00 |
| Jun 30, 2015 | 2,000.00 |
| Mar 31, 2015 | 1,000.00 |
| Sep 30, 2014 | 1,000.00 |
| Jun 30, 2014 | 1,000.00 |
| Mar 31, 2014 | 1,000.00 |